URT-PCR Designed for Human Tissue and mRNA Amplification and Quantitation
URT for all tested transcriptsmRNA specific PCRStandard RNA isolation techniques are acceptable – no additional purification stepsMultiple transcripts can be amplified from one total RNA sampleStandard housekeeper reference transcripts (i.e. β-actin, GAPDH) are valid controlsUsable with standard RT-PCR strategies/kits – only primers differQuantitation of low copy transcripts in small tissue samples is feasibleSensitivity similar to standard RT-PCR protocols
Gene expression assays, from traditional to microarraysQuantitative RT-PCR applicationsGene regulation researchGene expression phenotyping of cells and tissues for research or clinical molecular pathologySmall sample (e.g. micro dissection) or single cell expression assaysInter-individual expression phenotyping for disease susceptibility
The system has been readily employed in the common and currently used qualitative and real-time quantitative PCR protocols assessing gene expression in small samples of human tissues. The strategy has therefore proven to be universally applicable to all tested transcripts in all tested gene-expression assay contexts.
United States
Inventor: ZHENG, Bojian | SUI, Hongyan | LIN, Yongping
Priority Number: WO2010066112A1
IPC Current: C12N0015113 | A61K004800 | A61P003114
Assignee Applicant: The University of Hong Kong
Title: siRNA COMPOSITIONS AND METHODS FOR POTENTLY INHIBITING VIRAL INFECTION | COMPOSITIONS D'ARNSI ET PROCÉDÉS POUR INHIBER FORTEMENT UNE INFECTION VIRALE | COMPOSITIONS D’ARNSI ET PROCÉDÉS POUR INHIBER FORTEMENT UNE INFECTION VIRALE
Usefulness: siRNA COMPOSITIONS AND METHODS FOR POTENTLY INHIBITING VIRAL INFECTION | COMPOSITIONS D'ARNSI ET PROCÉDÉS POUR INHIBER FORTEMENT UNE INFECTION VIRALE | COMPOSITIONS D’ARNSI ET PROCÉDÉS POUR INHIBER FORTEMENT UNE INFECTION VIRALE
Summary: For preparing an agent for stimulating interleukin-6 (IL-6) production or for stimulating β -defensin production in a subject; for screening of potential antiviral agents; and as antiviral agents (all claimed), for prophylaxis or treatment of viral infection, preferably by H5N1 influenza virus.
Novelty: New small interfering RNAs useful for prophylaxis or treatment of influenza A virus infection, comprise pentanucleotide motif or reverse motif having specific nucleotide sequence
Biomedical
Pathogen
7,141,372
USA
